Novo Holdings to invest in KKR-backed Sylvan.

Novo Holdings, a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation, agreed to invest in KKR-backed Sylvan, a fungal biotechnology company. Financial terms are not disclosed. “Sylvan is delighted to welcome Novo Holdings as our latest investor and to have the continued support of KKR, who have been a terrific strategic partner in our value creation journey. With this latest milestone, we are in an excellent position to pursue our ambition to become a global leader in fungal biotechnology solutions across four unique markets: Food, Health, Agriculture, and Materials, and will look to leverage their global networks and expertise to take Sylvan to the next level of transformation,” Jackie Qi, Sylvan CEO.